Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. - Yang, Yunpeng; Zhou, Huaqiang; Tang, Linquan; Qiu, Sufang; Han, Yaqian; Ji, Dongmei; Chen, Xiaozhong; Lei, Feng; Qu, Song; Deng, Bin; Chen, Lusi; Huang, Jianli; et al. (Lancet, 2025)